Some time ago I reported on the concept that we might be able to raise human mitochondria, like bacteria, in a suitable medium, and use the mitochondrial-rich brew to supply new mitochondria to our living cells, replacing those that have aged and ceased to function well. This was based on a relatively new understanding that mitochondria have been observed moving from cell to cell based on energy needs for specific functions.  Mitrix Bio, a California research company, is currently at the forefront of mitochondrial research, aiming to address age-related diseases associated with mitochondrial dysfunction. Here are some key aspects of their groundbreaking work:

1. Mitlets: Mitrix Bio has developed a novel approach using “Mitlets”—young bioreactor-grown mitochondria encased in vesicles. These Mitlets have the potential to revolutionize regenerative medicine. By targeting specific organs and supplementing cells in need, they could significantly impact health outcomes.
2. Mitochondrial Dysfunction: Mitrix Bio focuses on understanding and mitigating mitochondrial dysfunction. Mitochondria play a crucial role in energy production, and their malfunction can lead to various health issues, including neurodegenerative diseases, cardiovascular conditions, and aging-related decline.
3. Therapeutic Applications: Their research explores therapeutic applications of Mitlets. These tiny mitochondrial packages could be used to rejuvenate damaged tissues, enhance cellular function, and potentially slow down the aging process.
4. Precision Medicine: Mitrix Bio aims to tailor treatments based on individual needs. By harnessing Mitlets, they hope to create personalized therapies that address specific mitochondrial deficiencies.
5. Collaborations and Partnerships: Mitrix Bio collaborates with academic institutions, research centers, and industry partners to advance mitochondrial science. Their interdisciplinary approach involves experts from various fields, including biology, bioengineering, and medicine.

Mitochondrial research is a complex and rapidly evolving field. Mitrix Bio’s work holds promise for improving human health: Here is an excerpt from their recent trial announcement:

We are proud to announce “The 130-Year-Old-Lifespan Trials”. Our volunteers – mostly in their 70s and 80s – aim to be the first people in history to break past the current “Lifespan Barrier” for the human species, which stands at 122. We aim to give them average lifespans of 130 with the health, strength, and appearance of 50. This trial will be conducted in our new division – Biotech Explorers. Because there will be very limited space to treat people in the early years, this treatment will be provided initially to current and former astronauts, and children with certain premature aging diseases.

We’ve known for the past year, from animal trials, that bioreactor-grown mitochondria transplantation had the potential to dramatically speed healing, fight infection, and extend lifespan. We could see in animal tests in the brain, muscles, immune system, and skin, that the effect was real. Other types of mitochondrial transplantation have already been safely used for in human patients for rare diseases. The 130-year-old lifespan treatment will be based on Bioreactor-Grown Mitochondrial Transplantation – a technique that our parent firm Mitrix Bio has been developing for several years. We are now making animals in the lab younger routinely.

Now the job in front of us, is to make the leap with careful, rigorous human trials targeting a 130-year-old lifespan. There is so much work to be done, but our team of top scientists from major universities and other research groups are ready to take on this challenge.

My closing thought on this is that we are on a major threshold of a practical strategy to reverse aging within the next decade!

To Your Greater Health and Fitness,

Frank